TER.NASDAQTeradyne, INC

Form 4: Teradyne Director Marilyn Matz Trades Shares

Sentiment:

Statement of Changes in Beneficial Ownership


Director Marilyn Matz of Teradyne, Inc. reported a transaction involving the sale of 400 shares of common stock on May 21, 2026, executed under a pre-established 10b5-1 trading plan.

Summary

  • Marilyn Matz, a Director at Teradyne, Inc., engaged in a stock transaction on May 21, 2026.
  • The transaction involved the sale of 400 shares of common stock.
  • This sale was conducted under a Rule 10b5-1 trading plan adopted on February 13, 2026.
  • Following the transaction, Matz beneficially owns 18,640.675 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine stock transaction by a director under a pre-established plan, with no indication of significant positive or negative company performance.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Teradyne, are standard disclosures for insider stock transactions. The use of a Rule 10b5-1 plan is a common strategy for executives and directors to manage their stock holdings while adhering to insider trading regulations.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Trading Plan AdoptionMarilyn Matz adopted a Rule 10b5-1 trading plan on February 13, 2026, for the purchase or sale of equity securities of the issuer.02/13/2026This plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), providing a framework for managing stock transactions in compliance with regulations.

Stakeholder Impact

  • Shareholders: The transaction represents a sale of shares by a director, which is a standard disclosure. The use of a 10b5-1 plan suggests a pre-determined strategy rather than a reaction to non-public information.

Key Dates

DateDescription
02/13/2026Adoption date of the Rule 10b5-1 trading plan.
05/21/2026Date of the reported stock transaction (sale of common stock).
05/26/2026Date the Form 4 was signed by the attorney-in-fact.

Keywords

Teradyne, Form 4, SEC Filing, Insider Trading, Stock Transaction, Director, Common Stock, 10b5-1 Plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.